| 耐多药结核病的现状与对策 |
| |
| 引用本文： | 王仲元.耐多药结核病的现状与对策[J].传染病信息,2011,24(2):117-120. |
| |
| 作者姓名： | 王仲元 |
| |
| 作者单位： | 解放军第三○九医院,全军结核病研究所结核三科,北京,100091 |
| |
| 基金项目： | 国家"十一五"科技重大专项 |
| |
| 摘 要： | 近10年,耐多药结核病全球形势严峻,2009年的监测结果 显示:初治肺结核患者耐多药率为0.0%～28.3%,复治肺结核患者耐多药率为0.0%～61.6%.我国是全球耐多药结核病高负担国家之一,耐多药和超级耐药结核病患者数均列世界首位.对此,最重要的是对其加强监测和进行准确诊断,强调早期合理用药和个体化的全程直接督导化...
|
| 关 键 词： | 结核 肺 抗药性 多药 结核分枝杆菌 |
Current status of multidrug-resistant tuberculosis and its countermeasures |
| |
| WANG Zhong-yuan.Current status of multidrug-resistant tuberculosis and its countermeasures[J].Infectious Disease Information,2011,24(2):117-120. |
| |
| Authors: | WANG Zhong-yuan |
| |
| Institution: | WANG Zhong-yuan The Third Department of Tuberculosis,Military Tuberculosis Institute,309 Hospital of PLA,Beijing 100091,China |
| |
| Abstract: | Multidrug-resistant tuberculosis(MDR-TB) has been a major global public health threat since the last decade.According to the results of the survey in 2009,primary MDR-TB was 0.0%-28.3% and acquired MDR-TB was 0.0%-61.6%.China is one of the global high-burden MDR-TB countries and its cases of both MDR-TB and extensively drug-resistant TB account for the largest proportion of such cases all over the world.So it has been suggested that close monitoring and accurate diagnosis of MDR-TB,rational use of drugs at an early stage and individualized directly-observed treatment strategy should be emphasized and enhanced,and the treatment should be guided by WHO’s suggestions. |
| |
| Keywords: | tuberculosis pulmonary drug resistance multiple Mycobacterium tuberculosis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
